HER2 Protein Overexpression, mRNA Expression, and DNA Amplification Across Solid Tumors: Comparison of Next-Generation Sequencing–Based Assays With Immunohistochemistry
JCO Precision Oncology · 2026-01 · 10 (1)
DOI: 10.1200/po-25-00413 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift JCO Precision Oncology, 2026-01. Verfasst von Michiko Nagamine und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Japan. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, RNA, Messenger, Immunohistochemistry, High-Throughput Nucleotide Sequencing. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE The tumor-agnostic approach has been increasingly adopted in precision oncology. Immunohistochemistry (IHC) is the standard biomarker testing for human epidermal growth factor receptor 2 (HER2)–targeted therapies, whereas next-generation sequencing (NGS) has been widely incorporated in routine clinical practices. Here, we investigated the concordance between NGS-based assays and IHC in HER2 testing. Interfering factors leading to discordant results between the assays were also studied. MATERIALS AND METHODS Over 78,000 solid tumors across various types from two independent cohorts in the United States and Japan were investigated for HER2 DNA copy number, mRNA expression, and protein overexpression by whole-exome sequencing (WES), whole-transcriptome sequencing (WTS), and IHC, respectively. RESULTS In the US cohort (n = 77,267), HER2 DNA amplification, mRNA overexpression, and IHC-positive (IHC-P) were detected in 4.9%, 10.1%, and 4.7% of the tumors, respectively. Positive results in at least one of the three assays were observed in 10.7% of tumors, while 3.9% were positive for all three assays. Using IHC as a comparator, WTS showed better sensitivity than WES but a lower positive predictive value. These results were consistent in the Japanese cohort (n = 1,225). Although the overall HER2 RNA expression level correlated well with IHC score and DNA copy number, the degree of correlation varied among tumor types. Heterogeneous distribution of IHC-P tumor cells was associated with discordant results between NGS-based assays and IHC. CONCLUSION HER2-positive status in protein, mRNA, and DNA showed concordance in general but varied among tumor types. NGS-based assays, especially WTS, could be a useful predictive tool for HER2 testing in tumor-agnostic settings. Intratumor heterogeneity in HER2 protein expression should be considered when bringing bulk sequencing tests into clinical settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Japan.
- Translational Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan.
- Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
- Division of Pathology, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, Japan.
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
- Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
ORCID-Profile: Michiko Nagamine, Takao Fujisawa, Yoshiaki Nakamura, Shigenori Kadowaki, Makoto Ueno, Shogen Boku, Yoshito Komatsu, Eiji Oki, Akitaka Makiyama, Chigusa Morizane, Susumu Okano, Hiroji Iwata, Kenjiro Namikawa, Yutaka Hatanaka, Kanako C Hatanaka, Kenichi Taguchi, David Spetzler, Milan Radovich, Daniel Magee, Takayuki Yoshino, Matthew Oberley, Takeshi Kuwata
Zitieren
APA
Nagamine, M., Fujisawa, T., Sakamoto, N., Nakamura, Y., Kadowaki, S., Ueno, M., Boku, S., Komatsu, Y., Oki, E., Makiyama, A., Nonomura, N., Morizane, C., Watari, H., Okano, S., Iwata, H., Namikawa, K., Hatanaka, Y., Hatanaka, K. C., Taguchi, K., …, & Kuwata, T. (2026). HER2 Protein Overexpression, mRNA Expression, and DNA Amplification Across Solid Tumors: Comparison of Next-Generation Sequencing–Based Assays With Immunohistochemistry. JCO Precision Oncology, 10(1). https://doi.org/10.1200/po-25-00413
Vancouver
Nagamine M, Fujisawa T, Sakamoto N, Nakamura Y, Kadowaki S, Ueno M, et al. HER2 Protein Overexpression, mRNA Expression, and DNA Amplification Across Solid Tumors: Comparison of Next-Generation Sequencing–Based Assays With Immunohistochemistry. JCO Precision Oncology. 2026;10(1). doi:10.1200/po-25-00413
BibTeX
@article{Nagamine2026,
author = {Nagamine, Michiko and Fujisawa, Takao and Sakamoto, Naoya and Nakamura, Yoshiaki and Kadowaki, Shigenori and Ueno, Makoto and Boku, Shogen and Komatsu, Yoshito and Oki, Eiji and Makiyama, Akitaka and Nonomura, Norio and Morizane, Chigusa and Watari, Hidemichi and Okano, Susumu and Iwata, Hiroji and Namikawa, Kenjiro and Hatanaka, Yutaka and Hatanaka, Kanako C and Taguchi, Kenichi and Spetzler, David and Radovich, Milan and Magee, Daniel and Yoshino, Takayuki and Oberley, Matthew and Kuwata, Takeshi},
title = {HER2 Protein Overexpression, mRNA Expression, and DNA Amplification Across Solid Tumors: Comparison of Next-Generation Sequencing–Based Assays With Immunohistochemistry},
journal = {JCO Precision Oncology},
year = {2026},
volume = {10},
number = {1},
doi = {10.1200/po-25-00413}
}
EUVIMED